Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Impath Inc. (IMPH) -- Ignore unavailable to you. Want to Upgrade?

To: stockid who wrote (58)	12/19/1998 8:54:00 AM
From: Ausdauer	Read Replies (1) \| Respond to of 68

Thread, Anybody home? This issue was woefully oversold of late. They will report record revenues on the year, robust growth year-over-year and have performed consistently since going public. The market's reaction to their earnings "warning" was way overdone. I had tracked the stock looking for a point of entry. I think I found it this past week. The service they provide seems to make alot of sense. Also, as more advanced and expensive therapies for malignancies develop this company will be able to provide important diagnostic and prognostic information, as well as predict possible responses to chemotherapeutic regimens. The important megatrend is the aging population and the swell of baby boomers entering into the age group where malignancies start to appear. The company also seems to be quite adept at growing their product lines via acquisitions and are keenly sensitive to shareholder value. All IMHO... Ausdauer